DR. BORIS BAGDASARIAN D.O. NPI 1598758062

NPI Details

DR. Boris Bagdasarian, D.O. is a hematology and oncology internal medicine in Glendale, CA with 33 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. DR. Boris Bagdasarian, D.O. NPI is 1598758062. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

The provider's business location address is:

1505 WILSON TER
SUITE 200
GLENDALE, CA
ZIP 91206-071
Phone: (818) 409-0105
Fax: (818) 409-0151

The NPI 1598758062 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram (HCPCS:Q5101)
• Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1568)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, atezolizumab, 10 mg (HCPCS:J9022)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, atropine sulfate, 0.01 mg (HCPCS:J0461)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg (HCPCS:Q5107)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Injection, fulvestrant, 25 mg (HCPCS:J9395)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Injection, rituximab-abbs, biosimilar, (truxima), 10 mg (HCPCS:Q5115)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Assessment of emotional or behavioral problems (HCPCS:96127)
• Biopsy of bone marrow (HCPCS:38221)
• Aspiration of bone marrow sample for diagnosis (HCPCS:38220)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)

The enumeration date for this NPI number is 8/30/2005 and was last updated on 3/13/2020.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available: